Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe Record History now shows a new revision entry v3.5.4, replacing the previous v3.5.3, reflecting a minor update to the page's history.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe Record History now shows Revision: v3.5.3, replacing the previous v3.5.2. This indicates the study record has been updated to a newer version.SummaryDifference0.1%

- Check41 days agoChange DetectedFooter revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3 from the record history.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision history updated to add v3.4.3 and remove v3.4.2.SummaryDifference0.1%

- Check105 days agoChange DetectedA new Revision: v3.4.2 entry was added to the record history, and a lengthy government funding status notice was removed from the page header. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.